119 related articles for article (PubMed ID: 36805958)
41. Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN).
Islam SS; Mokhtari RB; Akbari P; Hatina J; Yeger H; Farhat WA
Target Oncol; 2016 Apr; 11(2):209-27. PubMed ID: 26453055
[TBL] [Abstract][Full Text] [Related]
42. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
Reguera-Nuñez E; Xu P; Chow A; Man S; Hilberg F; Kerbel RS
J Exp Clin Cancer Res; 2019 Jan; 38(1):16. PubMed ID: 30635009
[TBL] [Abstract][Full Text] [Related]
43. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
44. Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer.
Bosch-Barrera J; Verdura S; Ruffinelli JC; Carcereny E; Sais E; Cuyàs E; Palmero R; Lopez-Bonet E; Hernández-Martínez A; Oliveras G; Buxó M; Izquierdo A; Morán T; Nadal E; Menendez JA
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439322
[TBL] [Abstract][Full Text] [Related]
45. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer.
Gust KM; McConkey DJ; Awrey S; Hegarty PK; Qing J; Bondaruk J; Ashkenazi A; Czerniak B; Dinney CP; Black PC
Mol Cancer Ther; 2013 Jul; 12(7):1245-54. PubMed ID: 23657946
[TBL] [Abstract][Full Text] [Related]
46. Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.
Tai WT; Shiau CW; Li YS; Chang CW; Huang JW; Hsueh TT; Yu HC; Chen KF
J Hepatol; 2014 Jul; 61(1):89-97. PubMed ID: 24657398
[TBL] [Abstract][Full Text] [Related]
47. Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP).
da Silva RF; Nogueira-Pangrazi E; Kido LA; Montico F; Arana S; Kumar D; Raina K; Agarwal R; Cagnon VHA
J Biomed Sci; 2017 May; 24(1):31. PubMed ID: 28499383
[TBL] [Abstract][Full Text] [Related]
48. Cigarette Smoke Containing Acrolein Contributes to Cisplatin Resistance in Human Bladder Cancers through the Regulation of HER2 Pathway or FGFR3 Pathway.
Hong JH; Tong ZJ; Wei TE; Lu YC; Huang CY; Huang CY; Chiang CH; Jaw FS; Cheng HW; Wang HT
Mol Cancer Ther; 2022 Jun; 21(6):1010-1019. PubMed ID: 35312783
[TBL] [Abstract][Full Text] [Related]
49. Nintedanib for the treatment of non-small-cell lung cancer.
Rashdan S; Hanna N
Expert Opin Pharmacother; 2014 Apr; 15(5):729-39. PubMed ID: 24597846
[TBL] [Abstract][Full Text] [Related]
50. FGFR3 Down-Regulation is Involved in bacillus Calmette-Guérin Induced Bladder Tumor Growth Inhibition.
Langle YV; Belgorosky D; Prack McCormick B; Sahores A; Góngora A; Baldi A; Lanari C; Lamb C; Eiján AM
J Urol; 2016 Jan; 195(1):188-97. PubMed ID: 26144336
[TBL] [Abstract][Full Text] [Related]
51. Antiangiogenic therapy with Nintedanib affects hypoxia, angiogenesis and apoptosis in the ventral prostate of TRAMP animals.
da Silva RF; Banzato TP; Alves LF; Carvalho JE; Agarwal R; Cagnon VHA
Cell Tissue Res; 2020 Feb; 379(2):407-420. PubMed ID: 31473819
[TBL] [Abstract][Full Text] [Related]
52. Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells.
Kim H; Lee SJ; Lee IK; Min SC; Sung HH; Jeong BC; Lee J; Park SH
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325639
[TBL] [Abstract][Full Text] [Related]
53. Isoquercitrin inhibits bladder cancer progression in vivo and in vitro by regulating the PI3K/Akt and PKC signaling pathways.
Chen F; Chen X; Yang D; Che X; Wang J; Li X; Zhang Z; Wang Q; Zheng W; Wang L; Wang X; Song X
Oncol Rep; 2016 Jul; 36(1):165-72. PubMed ID: 27177091
[TBL] [Abstract][Full Text] [Related]
54. Daidzein exerts anti-tumor activity against bladder cancer cells via inhibition of FGFR3 pathway.
He Y; Wu X; Cao Y; Hou Y; Chen H; Wu L; Lu L; Zhu W; Gu Y
Neoplasma; 2016; 63(4):523-31. PubMed ID: 27268915
[TBL] [Abstract][Full Text] [Related]
55. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
[TBL] [Abstract][Full Text] [Related]
56. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
57. Nintedanib inhibits keloid fibroblast functions by blocking the phosphorylation of multiple kinases and enhancing receptor internalization.
Zhou BY; Wang WB; Wu XL; Zhang WJ; Zhou GD; Gao Z; Liu W
Acta Pharmacol Sin; 2020 Sep; 41(9):1234-1245. PubMed ID: 32327724
[TBL] [Abstract][Full Text] [Related]
58. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
Kim Y; Lee SJ; Lee JY; Lee SH; Sun JM; Park K; An HJ; Cho JY; Kang EJ; Lee HY; Kim J; Keam B; Kim HR; Lee KE; Choi MY; Lee KH; Ahn MJ
Cancer; 2017 Jun; 123(11):1958-1964. PubMed ID: 28102887
[TBL] [Abstract][Full Text] [Related]
59. Augmentation of
Awasthi N; Schwarz MA; Zhang C; Schwarz RE
Mol Cancer Ther; 2018 Nov; 17(11):2353-2364. PubMed ID: 30166402
[TBL] [Abstract][Full Text] [Related]
60. PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer.
Kim KJ; Kim JW; Sung JH; Suh KJ; Lee JY; Kim SH; Lee JO; Kim JW; Kim YJ; Kim JH; Bang SM; Lee JS; Kim HK; Lee KW
Sci Rep; 2020 Jul; 10(1):12308. PubMed ID: 32704014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
